Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SI) Stock Competitors & Peer Comparison
See (T14.SI) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
Stock Comparison
T14.SI vs 42C.SI Comparison April 2026
T14.SI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, T14.SI stands at 4.9B. In comparison, 42C.SI has a market cap of 202.3M. Regarding current trading prices, T14.SI is priced at SGD 3.25, while 42C.SI trades at SGD 0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
T14.SI currently has a P/E ratio of 4.82, whereas 42C.SI's P/E ratio is -19.50. In terms of profitability, T14.SI's ROE is +0.42%, compared to 42C.SI's ROE of -4.51%. Regarding short-term risk, T14.SI is more volatile compared to 42C.SI. This indicates potentially higher risk in terms of short-term price fluctuations for T14.SI.Check 42C.SI's competition here